Anbio Biotechnology (NNNN): Revenue

Annual figures by period end, from SEC filings.

$8.65M

Year ended 2025-12-31

-28.4%

3-year compound annual growth

2022-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$8.65M	+5.6%	2026-04-07, From 2025-01-01
2024-12-31	$8.19M	+21.9%	2026-04-07, From 2024-01-01
2023-12-31	$6.71M	-71.5%	2026-04-07, From 2023-01-01
2022-12-31	$23.54M	n/a	2025-04-28, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Anbio Biotechnology (NNNN)	2025-12-31	$8.65M	+5.6%
Aspira Women's Health Inc. (AWHL)	2025-12-31	$9.22M	+0.4%
Biomerica Inc (BMRA)	2026-05-31	$4.45M	-16.2%
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	$4.05M	+115.6%
Immucell Corp (ICCC)	2025-12-31	$27.64M	+4.3%
Alpha Teknova, Inc. (TKNO)	2025-12-31	$40.52M	+7.4%
Volitionrx Ltd (VNRX)	2025-12-31	$1.73M	+40.0%
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	$1.54M	-78.0%
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	$67.67M	+16.9%

Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗